An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1

Protein Science

Volumn 21, Issue 3, 2012, Pages 418-432

  Alsenaidy, Mohammad A ^a   Wang, Tingting ^a   Kim, Jae Hyun ^c   Joshi, Sangeeta B ^a   Lee, Jihun ^b   Blaber, Michael ^b   Volkin, David B ^a   Middaugh, C Russell ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

^c University of Kansas   (United States)

Author keywords

Circular dichroism; Conformation; EPDs; FGF 1; Fluorescence; Heparin; Light scattering; Stability; Structure

Indexed keywords

1 ANILINO 8 NAPHTHALNESULFONATE; FIBROBLAST GROWTH FACTOR 1; HEPARIN; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; CIRCULAR DICHROISM; CONTROLLED STUDY; EMPIRICAL PHASE DIAGRAM; ENVIRONMENTAL STRESS; FLUORESCENCE SPECTROSCOPY; MUTATION; PH; PLOTS AND CURVES; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN STRUCTURE; SPECTROSCOPY; TEMPERATURE;

BIOPHYSICAL PHENOMENA; CIRCULAR DICHROISM; FIBROBLAST GROWTH FACTOR 1; HEPARIN; HUMANS; HYDROGEN-ION CONCENTRATION; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY; SPECTROMETRY, FLUORESCENCE; TEMPERATURE;

EID: 84863177542     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2008     Document Type: Article

References (46)

1. Ioli V, Wiens B, Mellin T, Thomas K, Ellis R, Ryan J, White CJ (1992) Effect of topically applied acidic fibroblast growth factor (FGF-1) on healing of chronic venous stasis and diabetic ulcers. Abstracts of the 5th Annual Symposium on Advanced Wound Care. p 150.
2. Schumacher B, Pecher P, von Specht BU, Stegmann T (1998) Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 97:645-650. (Pubitemid 28090957)
3. Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, Sequeira R, Kent CK, Bacchetta M, Goldman C, Salenius JP, Schmieder FA, Pilsudski R (2002)Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35:930-936. (Pubitemid 44718562)
4. Wagoner L, Merrill W, Jacobs J, Conway G, Boehmer J, Thomas K, Stegmann T (2007) Angiogenesis protein therapy with human fibroblast growth factor (FGF-1): results of a phase I open label, dose escalation study in subjects with CAD not eligible for PCI or CABG. Circulation 116:443.
5. Copeland RA, Ji H, Halfpenny AJ, Williams RW, Thompson KC, Herber WK, Thomas KA, Bruner MW, Ryan JA, Marquis-Omer D, Sanyal G, Sitrin RD, Yamazaki S, Middaugh CR (1991) The structure of human acidic fibroblast growth factor and its interaction with heparin. Arch Biochem Biophys 289:53-61.
6. Lee J, Blaber M (2009) The interaction between thermostability and buried free cysteines in regulating the functional half-life of fibroblast growth factor-1. J Mol Biol 393:113-127.
7. Tsai PK, Volkin DB, Dabora JM, Thompson KC, Bruner MW, Gress JO, Matuszewska B, Keogan M, Bondi JV, Middaugh CR (1993) Formulation design of acidic fibroblast growth factor. Pharm Res 10:649-659. (Pubitemid 23152307)
8. Mach H, Volkin DB, Burke CJ, Middaugh CR, Linhardt RJ, Fromm JR, Loganathan D, Mattsson L (1993) Nature of the interaction of heparin with acidic fibroblast growth factor. Biochemistry 32:5480-5489. (Pubitemid 23167992)
9. Volkin DB, Tsai PK, Dabora JM, Gress JO, Burke CJ, Linhardt RJ, Middaugh CR (1993) Physical stabilization of acidic fibroblast growth factor by polyanions. Arch Biochem Biophys 300:30-41. (Pubitemid 23225714)
10. Fan H, Li H, Zhang M, Middaugh CR (2007) Effects of solutes on empirical phase diagrams of human fibroblast growth factor 1. J Pharm Sci 96:1490-1503. (Pubitemid 46953765)
11. Harris JM, Chess RB (2003) Effect of PEGylation on pharmaceuticals. Nature Rev Drug Discov 2:214-221.
12. Chapman AP (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54:531-545.
13. Monfardini C, Schiavon O, Caliceti P, Morpurgo M, Harris JM, Veronese FM (1995) A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem 6:62-69.
14. Basu A, Yang K,WangM, Liu S, Chintala R, Palm T, Zhao H, Peng P,Wu D, Zhang Z,Hua J, HsiehMC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D (2006) Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem17:618-630. (Pubitemid 43794371)
15. Kurtzman AL, Govindarajan S, Vahle K, Jones JT, Heinrichs V, Patten PA (2001) Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Curr Opin Biotechnol 12:4171-4197.
16. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR (2003) Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study. J Pharm Sci 92:1805-1820. (Pubitemid 37071814)
17. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR (2011) Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 100:4171-4197.
18. Chirino AJ, Mire-Sluis A (2004) Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 22:1383-1391. (Pubitemid 39482857)
19. Lubiniecki AS, Marcia Federici M (2006) Comparability is not just analytical equivalence. Biologicals 34:45-47.
20. Lubiniecki A, Volkin DB, Federici M, Bond MD, Nedved ML, Hendricks L, Mehndiratta P, Bruner M, Burman S, Dalmonte P, Kline J, Ni A, Panek ME, Pikounis B, Powers G, Vafa O, Siegel R (2011) Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals 39:9-22.
21. Schenerman MA, Hope JN, Kletke C, Singh JK, Kimura R, Tsao EI, Folena-Wasserman G (1999) Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scaleup for manufacturing. Biologicals 27:203-215. (Pubitemid 30077322)
22. Brych SR, Dubey VK, Bienkiewicz E, Lee J, Logan TM, Blaber M (2004) Symmetric primary and tertiary structure mutations within a symmetric superfold: a solution, not a constraint, to achieve a foldable polypeptide. J Mol Biol 344:769-780. (Pubitemid 39469219)
23. Culajay JF, Blaber SI, Khurana A, Blaber M (2000) Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life. Biochemistry 39:7153-7158. (Pubitemid 30413104)
24. Dubey VK, Lee J, Somasundaram T, Blaber S, Blaber M (2007) Spackling the crack: stabilizing human fibroblast growth factor-1 by targeting the N and C terminus beta-strand interactions. J Mol Biol 371:256-268. (Pubitemid 47030467)
25. Kim J, Brych SR, Lee J, Logan TM, Blaber M (2003) Identification of a key structural element for protein folding within beta-hairpin turns. J Mol Biol 328:951-961. (Pubitemid 36506899)
26. Lee J, BlaberM(2011) Experimental support for the evolution of symmetric protein architecture from a simple peptide motif. Proc Natl Acad Sci U S A 108:126-130.
27. Lee J, Blaber M (2009) Structural basis of conserved cysteine in the fibroblast growth factor family: evidence for a vestigial half-cystine. J Mol Biol 393:128-139.
28. Lee J, Dubey VK, Longo LM, Blaber M (2008) A logical OR redundancy within the Asx-Pro-Asx-Gly type I beta-turn motif. J Mol Biol 377:1251-1264.
29. Lee J, Blaber SI, Dubey VK, Blaber M (2011) A polypeptide "building block" for the beta-trefoil fold identified by "top-down symmetric deconstruction". J Mol Biol 407:744-763.
30. Srimathi T, Kumar TK, Kathir KM, Chi YH, Srisailam S, Lin WY, Chiu IM, Yu C (2003) Structurally homologous all beta-barrel proteins adopt different mechanisms of folding. Biophys J 85:459-472. (Pubitemid 36753650)
31. Manning MC, Illangasekare M, Woody RW (1988) Circular dichroism studies of distorted alpha-helices, twisted beta-sheets, and beta turns. Biophys Chem 31: 77-86.
32. Khan MY, Villanueva G, Newman SA (1989) On the origin of the positive band in the far-ultraviolet circular dichroic spectrum of fibronectin. J Biol Chem 264: 2139-2142. (Pubitemid 19057684)
33. Berova N, Nakanishi K, Woody RW (2000) Circular dichroism: principles and applications, 2nd ed. Wiley.
34. Mach H, Middaugh CR (1995) Interaction of partially structured states of acidic fibroblast growth factor with phospholipid membranes. Biochemistry 34:9913-9920.
35. Mach H, Ryan JA, Burke CJ, Volkin DB, Middaugh CR (1993) Partially structured self-associating states of acidic fibroblast growth factor. Biochemistry 32: 7703-7711. (Pubitemid 23240815)
36. Pineda-Lucena A, Nunez De Castro I, Lozano RM, Munoz-Willery I, Zazo M, Gimenez-Gallego G (1994) Effect of low pH and heparin on the structure of acidic fibroblast growth factor. Eur J Biochem 222:425-431. (Pubitemid 24204911)
37. Semisotnov GV, Rodionova NA, Razgulyaev OI, Uversky VN, Gripas AF, Gilmanshin RI (1991) Study of the "molten globule" intermediate state in protein folding by a hydrophobic fluorescent probe. Biopolymers 31: 119-128.
38. Matulis D, Lovrien R (1998) 1-Anilino-8-naphthalene sulfonate anion-protein binding depends primarily on ion pair formation. Biophys J 74:422-429. (Pubitemid 28041769)
39. Joshi S, Bhambhani A, Zeng Y, Middaugh CR (2010) Formulation and process development strategies for manufacturing biopharmaceuticals. Wiley & Sons Publication.
40. Linemeyer DL, Menke JG, Kelly LJ, DiSalvo J, Soderman D, Schaeffer MT, Ortega S, Gimenez-Gallego G, Thomas KA (1990) Disulfide bonds are neither required, present, nor compatible with full activity of human recombinant acidic fibroblast growth factor. Growth Factors 3:287-298.
41. Blaber M, DiSalvo J, Thomas KA (1996) X-ray crystal structure of human acidic fibroblast growth factor. Biochemistry 35:2086-2094. (Pubitemid 26071642)
42. Gimenez-Gallego G, Conn G, Hatcher VB, Thomas KA (1986) The complete amino acid sequence of human brain-derived acidic fibroblast growth factor. Biochem Biophys Res Commun 138:611-617. (Pubitemid 16013182)
43. Cuevas P, Carceller F, Ortega S, Zazo M, Nieto I, Gimenez-Gallego G (1991) Hypotensive activity of fibroblast growth factor. Science 254:1208-1210. (Pubitemid 21917455)
44. Brych SR, Blaber SI, Logan TM, Blaber M (2001) Structure and stability effects of mutations designed to increase the primary sequence symmetry within the core region of a beta-trefoil. Protein Sci 10:2587-2599. (Pubitemid 33091582)
45. Zazo M, Lozano RM, Ortega S, Varela J, Diaz-Orejas R, Ramirez JM, Gimenez-Gallego G (1992) High-level synthesis in Escherichia coli of shortened and full-length human acidic fibroblast growth factor and purification in a form stable in aqueous solutions. Gene 113:231-238.
46. Lee J, Blaber M (2010) Increased functional half-life of fibroblast growth factor-1by recovering a vestigial disulfide bond. J Proteins Proteomics 1:37-42.